RESUMO
Biaryl atropisomers are key structural components in chiral ligands, chiral functional materials, natural products, and bioactive compounds, and their asymmetric syntheses have been reported by many groups. In contrast, although the scientific community has long been aware of atropisomers due to rotational restriction around N-C bonds, they have attracted scant attention and have remained an unexplored research area. In particular, their catalytic asymmetric synthesis and the synthetic applications were unknown until recently. This Account describes studies conducted by our group on the catalytic enantioselective syntheses of N-C axially chiral compounds and their applications in asymmetric reactions.In the presence of a chiral Pd catalyst, the reactions of achiral secondary ortho-tert-butylanilides with 4-iodonitrobenzene proceeded in a highly enantioselective manner (up to 96% ee), affording N-C axially chiral N-arylated ortho-tert-butylanilides in good yields. The application of the present chiral Pd-catalyzed N-arylation reaction to an intramolecular version gave N-C axially chiral lactams with high optical purity (up to 98% ee). These reactions were the first highly enantioselective syntheses of N-C axially chiral compounds with a chiral catalyst. Since the publication of these reactions, N-C axially chiral compounds have been widely accepted as new target molecules for catalytic asymmetric reactions. Furthermore, chiral-Pd-catalyzed intramolecular N-arylations were applied to the enantioselective syntheses of N-C axially chiral quinoline-4-one and phenanthridin-6-one derivatives. We also succeeded in the enantioselective syntheses of various N-C axially chiral compounds using other chiral Pd-catalyzed reactions. That is, optically active N-C axially chiral N-(2-tert-butylphenyl)indoles, 3-(2-bromophenyl)quinazolin-4-ones, and N-(2-tert-butylphenyl)sulfonamides were obtained through chiral Pd-catalyzed 5-endo-hydroaminocyclization, monohydrodebromination (reductive asymmetric desymmetrization), and Tsuji-Trost N-allylation, respectively. The study of the catalytic asymmetric synthesis of axially chiral indoles has contributed to the development of not only N-C axially chiral chemistry but also the chemistry of axially chiral indoles. Subsequently, the catalytic asymmetric syntheses of various indole derivatives bearing a C-C chiral axis as well as an N-C chiral axis have been reported by many groups. Moreover, axially chiral quinazlolin-4-one derivatives, which were obtained through chiral Pd-catalyzed asymmetric desymmetrization, are pharmaceutically attractive compounds; for example, 2-methyl-3-(2-bromophenyl)quinazolin-4-one product is a mebroqualone possessing GABA agonist activity.Most of the N-C axially chiral products have satisfactory rotational stability for synthetic applications, and their synthetic utility was also demonstrated through application to chiral enolate chemistry. That is, the reaction of various alkyl halides with the enolate prepared from the optically active anilide, lactam, and quinazolinone products proceeded with high diastereoselectivity by asymmetric induction due to the N-C axial chirality.At the present time, N-C axially chiral chemistry has become a popular research area, especially in synthetic organic chemistry, and original papers on the catalytic asymmetric syntheses of various N-C axially chiral compounds and their synthetic applications have been published.
Assuntos
Produtos Biológicos/síntese química , Carbono/química , Nitrogênio/química , Paládio/química , Produtos Biológicos/química , Catálise , Ciclização , Agonistas GABAérgicos/química , Agonistas GABAérgicos/metabolismo , Indóis/síntese química , Indóis/química , Conformação Molecular , Quinolonas/síntese química , Quinolonas/química , Receptores de GABA/química , Receptores de GABA/metabolismo , Estereoisomerismo , Sulfonamidas/síntese química , Sulfonamidas/químicaRESUMO
Targeted manipulations of neural activity are essential approaches in neuroscience and neurology, but monitoring such procedures in the living brain remains a significant challenge. Here we introduce a paramagnetic analog of the drug muscimol that enables targeted neural inactivation to be performed with feedback from magnetic resonance imaging. We validate pharmacological properties of the compound in vitro, and show that its distribution in vivo reliably predicts perturbations to brain activity.
Assuntos
Ondas Encefálicas/fisiologia , Encéfalo/fisiologia , Imageamento por Ressonância Magnética/métodos , Muscimol/farmacologia , Animais , Meios de Contraste/farmacologia , Agonistas GABAérgicos/química , Masculino , Muscimol/análogos & derivados , Ratos Sprague-Dawley , Ácido gama-Aminobutírico/químicaRESUMO
Padsevonil is an antiepileptic drug (AED) candidate synthesized in a medicinal chemistry program initiated to rationally design compounds with high affinity for synaptic vesicle 2 (SV2) proteins and low-to-moderate affinity for the benzodiazepine binding site on GABAA receptors. The pharmacological profile of padsevonil was characterized in binding and electrophysiological experiments. At recombinant SV2 proteins, padsevonil's affinity for SV2A was greater than that of levetiracetam and brivaracetam (pKi 8.5, 5.2, and 6.6, respectively). Unlike the latter AEDs, both selective SV2A ligands, padsevonil also displayed high affinity for the SV2B and SV2C isoforms (pKi 7.9 and 8.5, respectively). Padsevonil's interaction with SV2A differed from that of levetiracetam and brivaracetam; it exhibited slower binding kinetics: dissociation t 1/2 30 minutes from the human protein at 37°C compared with <0.5 minute for levetiracetam and brivaracetam. In addition, its binding was not potentiated by the allosteric modulator UCB1244283. At recombinant GABAA receptors, padsevonil displayed low to moderate affinity (pIC50≤6.1) for the benzodiazepine site, and in electrophysiological studies, its relative efficacy compared with zolpidem (full-agonist reference drug) was 40%, indicating partial agonist properties. In in vivo (mice) receptor occupancy studies, padsevonil exhibited SV2A occupancy at low ED50 (0.2 mg/kg) and benzodiazepine site occupancy at higher doses (ED50 36 mg/kg), supporting in vitro results. Padsevonil's selectivity for its intended targets was confirmed in profiling studies, where it lacked significant effects on a wide variety of ion channels, receptors, transporters, and enzymes. Padsevonil is a first-in-class AED candidate with a unique target profile allowing for presynaptic and postsynaptic activity. SIGNIFICANCE STATEMENT: Padsevonil is an antiepileptic drug candidate developed as a single molecular entity interacting with both presynaptic and postsynaptic targets. Results of in vitro and in vivo radioligand binding assays confirmed this target profile: padsevonil displayed nanomolar affinity for the three synaptic vesicle 2 protein isoforms (SV2A, B, and C) and micromolar affinity for the benzodiazepine binding site on GABAA receptors. Furthermore, padsevonil showed greater affinity for and slower binding kinetics at SV2A than the selective SV2A ligands, levetiracetam, and brivaracetam.
Assuntos
Anticonvulsivantes/farmacocinética , Agonistas GABAérgicos/farmacocinética , Imidazóis/farmacocinética , Glicoproteínas de Membrana/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Pirrolidinonas/farmacocinética , Receptores de GABA-A/metabolismo , Tiadiazóis/farmacocinética , Animais , Anticonvulsivantes/química , Células COS , Chlorocebus aethiops , Agonistas GABAérgicos/química , Células HEK293 , Humanos , Imidazóis/química , Cinética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Ligação Proteica , Pirrolidinonas/química , Ratos , Ratos Sprague-Dawley , Tiadiazóis/químicaRESUMO
Anxiolytic activity has been associated with GABAA α2 and α3 subunits. Several target compounds were identified and required in C-14 labeled form to enable a better understanding of their drug metabolism and pharmacokinetic properties. AZD7325 is a selective GABAA α2 and α3 receptor modulator intended for the treatment of anxiety through oral administration. A great number of AZD7325 metabolites were observed across species in vivo, whose identification was aided by [14 C]AZD7325. An interesting metabolic cyclization and aromatization pathway leading to the tricyclic core of M9 and the oxidative pathways to M10 and M42 are presented.
Assuntos
Agonistas GABAérgicos/química , Compostos Heterocíclicos com 2 Anéis/química , Inativação Metabólica , Animais , Radioisótopos de Carbono/química , Agonistas GABAérgicos/farmacocinética , Eliminação Hepatobiliar , Compostos Heterocíclicos com 2 Anéis/farmacocinética , RatosRESUMO
Halogenated analogues of the neurotoxic alkaloid muscimol were prepared with fluorine, iodine or trifluoromethyl at the 4 position of the isoxazole ring system. These compounds were investigated as agonists for GABAA receptors. Only the C-4 fluorine-containing analogue proved to be an active compound in these assays. The fluoro analogue was less active than muscimol, however it showed differential activity between synaptic (α1 ß2 γ2 ) and extrasynaptic (α4 ß2 γ) GABAA receptors, having a similar potency to the neurotransmitter GABA for the extrasynaptic (α4 ß2 γ) receptor.
Assuntos
Flúor/química , Agonistas GABAérgicos/química , Muscimol/química , Animais , Cristalografia por Raios X , Agonistas GABAérgicos/síntese química , Agonistas GABAérgicos/metabolismo , Conformação Molecular , Muscimol/síntese química , Muscimol/metabolismo , Oócitos/metabolismo , Receptores de GABA-A/genética , Receptores de GABA-A/metabolismo , Xenopus laevis/crescimento & desenvolvimento , Xenopus laevis/metabolismoRESUMO
A series of N-(2-(benzoyl/4-chlorobenzoyl)-benzofuran- 3-yl)-2-(substituted)-acetamide derivatives (4a-l, 5a-l) was synthesized in good yield. All synthesized compounds were in agreement with elemental and spectral data. The anticonvulsant activity of all synthesized compounds was assessed against the maximal electroshock induced seizures (MES) model in mice. Neurotoxicity was evaluated using the rotarod method. The majority of compounds exhibited anticonvulsant activity at a dose of 30 mg kg-1 body mass during 0.5-4 h, indicating their ability to prevent seizure spread at low doses. Relative to phenytoin, [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(cyclohexyl( methyl) amino)-acetamide] (5i) and [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-methylpiperidin-1- yl)-acetamide] (5c) demonstrated comparable relative anticonvulsant potency of 0.74 and 0.72, respectively, whereas [(N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-(furan-2-carbonyl)-piperazin-1-yl)-acetamide] (5f) exhibited the lowest relative potency of 0.16. The ALD50 of tested compounds ranged from 1.604 to 1.675 mmol kg-1 body mass. The ED50 of synthesized compounds ranged from 0.055 to 0.259 mmol kg-1 (~23.4 to 127.6 mg kg-1) body mass. The pharmacophore mapping of the examined compounds on standard drugs (phenobarbital, phenytoin, ralitolin and carbamazepine) strongly suggests that these compounds may exert their anticonvulsant activity via the same established mechanism as that of known drugs.
Assuntos
4-Aminobutirato Transaminase/metabolismo , Anticonvulsivantes/uso terapêutico , Benzofuranos/uso terapêutico , Desenho de Fármacos , Modelos Moleculares , Convulsões/prevenção & controle , 4-Aminobutirato Transaminase/química , Acetamidas/efeitos adversos , Acetamidas/química , Acetamidas/metabolismo , Acetamidas/uso terapêutico , Animais , Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/química , Anticonvulsivantes/metabolismo , Benzofuranos/efeitos adversos , Benzofuranos/química , Benzofuranos/metabolismo , Sítios de Ligação , Cerebelo/efeitos dos fármacos , Cerebelo/metabolismo , Relação Dose-Resposta a Droga , Agonistas GABAérgicos/efeitos adversos , Agonistas GABAérgicos/química , Agonistas GABAérgicos/metabolismo , Agonistas GABAérgicos/uso terapêutico , Glicina/efeitos adversos , Glicina/análogos & derivados , Glicina/química , Glicina/metabolismo , Glicina/uso terapêutico , Dose Letal Mediana , Masculino , Bulbo/efeitos dos fármacos , Bulbo/metabolismo , Mesencéfalo/efeitos dos fármacos , Mesencéfalo/metabolismo , Camundongos , Simulação de Acoplamento Molecular , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Síndromes Neurotóxicas/etiologia , Síndromes Neurotóxicas/metabolismo , Ratos Wistar , Sus scrofa , Ácido gama-Aminobutírico/química , Ácido gama-Aminobutírico/metabolismoRESUMO
Synaptic GABAA receptors are primary mediators of rapid inhibition in the brain and play a key role in the pathophysiology of epilepsy and other neurologic disorders. The δ-subunit GABAA receptors are expressed extrasynaptically in the dentate gyrus and contribute to tonic inhibition, promoting network shunting as well as reducing seizure susceptibility. However, the neurosteroid structure-function relationship at δGABA(A) receptors within the native hippocampus neurons remains unclear. Here we report a structure-activity relationship for neurosteroid modulation of extrasynaptic GABAA receptor-mediated tonic inhibition in the murine dentate gyrus granule cells. We recorded neurosteroid allosteric potentiation of GABA as well as direct activation of tonic currents using a wide array of natural and synthetic neurosteroids. Our results shows that, for all neurosteroids, the C3α-OH group remains obligatory for extrasynaptic receptor functional activity, as C3ß-OH epimers were inactive in activating tonic currents. Allopregnanolone and related pregnane analogs exhibited the highest potency and maximal efficacy in promoting tonic currents. Alterations at the C17 or C20 region of the neurosteroid molecule drastically altered the transduction kinetics of tonic current activation. The androstane analogs had the weakest modulatory response among the analogs tested. Neurosteroid potentiation of tonic currents was completely (approximately 95%) diminished in granule cells from δ-knockout mice, suggesting that δ-subunit receptors are essential for neurosteroid activity. The neurosteroid sensitivity of δGABA(A) receptors was confirmed at the systems level using a 6-Hz seizure test. A consensus neurosteroid pharmacophore model at extrasynaptic δGABA(A) receptors is proposed based on a structure-activity relationship for activation of tonic current and seizure protection.
Assuntos
Agonistas GABAérgicos/farmacologia , Neurotransmissores/farmacologia , Receptores de GABA-A/efeitos dos fármacos , Animais , Anticonvulsivantes/farmacologia , Giro Denteado/efeitos dos fármacos , Giro Denteado/metabolismo , Agonistas GABAérgicos/química , Moduladores GABAérgicos/farmacologia , Técnicas In Vitro , Interneurônios/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Midazolam/farmacologia , Neurônios/efeitos dos fármacos , Neurotransmissores/química , Pregnanos/farmacologia , Pregnanolona/farmacologia , Receptores de GABA-A/genética , Convulsões/prevenção & controle , Relação Estrutura-AtividadeRESUMO
An γ-aminobutyric acid type B (GABAB)-receptor mediates slow and prolonged synaptic inhibition in the central nervous system, which represents an interesting target for the treatment of various diseases and disorders of the central nervous system. To date, only one activator of the GABAB-receptor, baclofen, is on the market for the treatment of spasticity. Inhibitors of the GABAB-receptor, such as antagonists, show anti-absence seizure activity and pro-cognitive properties. In a search for allosteric compounds of the GABAB-receptor, although several positive allosteric modulators have been developed, it is only recently that the first negative allosteric modulator (NAM), CLH304a (also named Compound 14), has been reported. In the present study, we provide further information on the mechanism of action of CLH304a, and also show the possibility of designing more NAMs, such as CLH391 and CLH393, based on the structure of CLH304a. First we show that CLH304a inhibits native GABAB-receptor activity in cultured cerebellar granular neurons. We then show that CLH304a has inverse agonist properties and non-competitively inhibits the effect of agonists, indicating that it binds at a different site to GABA. The GABAB-receptor is a mandatory heterodimer made of GB1 subunits, in which agonists bind, and GB2 subunits, which activate G-proteins. By using various combinations made up of wild-type and/or mutated GB1 and GB2 subunits, we show that CLH304a acts on the heptahelical domain of GB2 subunits. These data revealed the possibility of designing innovative NAMs acting in the heptahelical domain of the GB2 subunits, offering novel possibilities for therapeutic intervention based on GABAB-receptor inhibition.
Assuntos
Agonistas GABAérgicos/farmacologia , Cetoácidos/farmacologia , Fenóis/farmacologia , Receptores de GABA-B/metabolismo , Transdução de Sinais , Regulação Alostérica , Animais , Sítios de Ligação , Agonistas GABAérgicos/química , Regulação da Expressão Gênica , Células HEK293 , Humanos , Cetoácidos/química , Camundongos , Modelos Moleculares , Estrutura Molecular , Fenóis/química , Conformação Proteica , Subunidades Proteicas , Receptores de GABA-B/genética , Relação Estrutura-AtividadeRESUMO
Analogues of the neurotransmitter GABA containing unsaturated bonds are restricted in the conformations they can attain. This review traces three such analogues from their synthesis to their use as neurochemicals. trans-4-Aminocrotonic acid was the first conformationally restricted analogue to be extensively studied. It acts like GABA across a range of macromolecules from receptors to transporters. It acts similarly to GABA on ionotropic receptors. cis-4-Aminocrotonic acid selectively activates bicuculline-insensitive GABAC receptors. 4-Aminotetrolic acid, containing a triple bond, activates bicuculline-sensitive GABAA receptors. These findings indicate that GABA activates GABAA receptors in extended conformations and GABAC receptors in folded conformations. These and related analogues are important for the molecular modelling of ionotropic GABA receptors and to the development of new agents acting selectively on these receptors.
Assuntos
Aminobutiratos/química , Aminobutiratos/farmacologia , Crotonatos/química , Crotonatos/farmacologia , Animais , Agonistas GABAérgicos/química , Agonistas GABAérgicos/farmacologia , Antagonistas GABAérgicos/química , Antagonistas GABAérgicos/farmacologia , Humanos , Neurotransmissores/química , Neurotransmissores/farmacologia , Receptores de GABA/metabolismo , Receptores de GABA-A/metabolismo , Estereoisomerismo , Ácido gama-Aminobutírico/análogos & derivados , Ácido gama-Aminobutírico/química , Ácido gama-Aminobutírico/farmacologiaRESUMO
Chemical manufacturing is conducted using either batch systems or continuous-flow systems. Flow systems have several advantages over batch systems, particularly in terms of productivity, heat and mixing efficiency, safety, and reproducibility. However, for over half a century, pharmaceutical manufacturing has used batch systems because the synthesis of complex molecules such as drugs has been difficult to achieve with continuous-flow systems. Here we describe the continuous-flow synthesis of drugs using only columns packed with heterogeneous catalysts. Commercially available starting materials were successively passed through four columns containing achiral and chiral heterogeneous catalysts to produce (R)-rolipram, an anti-inflammatory drug and one of the family of γ-aminobutyric acid (GABA) derivatives. In addition, simply by replacing a column packed with a chiral heterogeneous catalyst with another column packed with the opposing enantiomer, we obtained antipole (S)-rolipram. Similarly, we also synthesized (R)-phenibut, another drug belonging to the GABA family. These flow systems are simple and stable with no leaching of metal catalysts. Our results demonstrate that multistep (eight steps in this case) chemical transformations for drug synthesis can proceed smoothly under flow conditions using only heterogeneous catalysts, without the isolation of any intermediates and without the separation of any catalysts, co-products, by-products, and excess reagents. We anticipate that such syntheses will be useful in pharmaceutical manufacturing.
Assuntos
Técnicas de Química Sintética/instrumentação , Técnicas de Química Sintética/métodos , Rolipram/síntese química , Antidepressivos , Catálise , Agonistas GABAérgicos/síntese química , Agonistas GABAérgicos/química , Estrutura Molecular , Rolipram/química , Estereoisomerismo , Ácido gama-Aminobutírico/análogos & derivados , Ácido gama-Aminobutírico/síntese química , Ácido gama-Aminobutírico/químicaRESUMO
Since the discovery of the GABA(B) agonist and muscle relaxant baclofen, there have been substantial advancements in the development of compounds that activate the GABA(B) receptor as agonists or positive allosteric modulators. For the agonists, most of the existing structure-activity data apply to understanding the role of substituents on the backbone of GABA as well as replacing the carboxylic acid and amine groups. In the cases of the positive allosteric modulators, the allosteric binding site(s) and structure-activity relationships are less well-defined; however, multiple classes of molecules have been discovered. The recent report of the X-ray structure of the GABA(B) receptor with bound agonists and antagonists provides new insights for the development of compounds that bind the orthosteric site of this receptor. From a therapeutic perspective, these data have enabled efforts in drug discovery in areas of addiction-related behavior, the treatment of anxiety, and the control of muscle contractility.
Assuntos
Agonistas GABAérgicos/farmacologia , Moduladores GABAérgicos/farmacologia , Receptores de GABA-B/efeitos dos fármacos , Animais , Agonistas GABAérgicos/química , Antagonistas GABAérgicos/química , Antagonistas GABAérgicos/farmacologia , Moduladores GABAérgicos/síntese química , Humanos , Conformação Molecular , Receptores de GABA-B/química , Relação Estrutura-AtividadeRESUMO
A series of ß-amino acids with lipophilic diaromatic side chain was synthesized and characterized pharmacologically on mouse γ-amino butyric acid (GABA) transporter subtypes mGAT1-4 in order to investigate structure activity relationships (SAR) for mGAT2 (corresponding to hBGT-1). Variation in the lipophilic diaromatic side chain was probed to understand the role of the side chain for activity. This yielded several selective compounds of which the best (1R,2S)-5a was more than 10 fold selective towards other subtypes, although potency was moderate. A docking study was performed to investigate possible binding modes of the compounds in mGAT2 suggesting a binding mode similar to that proposed for Tiagabine in hGAT1. Specific interactions between the transporter and the amino acid part of the ligands may account for a reverted preference towards mGAT2 over mGAT1.
Assuntos
Aminoácidos/química , Proteínas de Transporte/antagonistas & inibidores , Proteínas da Membrana Plasmática de Transporte de GABA/química , Inibidores da Captação de GABA/química , Aminoácidos/síntese química , Animais , Proteínas de Transporte/química , Agonistas GABAérgicos/química , Inibidores da Captação de GABA/síntese química , Células HEK293 , Humanos , Ligantes , Camundongos , Simulação de Acoplamento Molecular , Estrutura Molecular , Ácidos Nipecóticos/química , Isoformas de Proteínas/química , Relação Estrutura-Atividade , TiagabinaRESUMO
Behavior is increasingly reported as a sensitive and early indicator of toxicant stress in aquatic organisms. However, the systematic understanding of behavioral effects and comparisons between effect profiles is hampered because the available studies are limited to few chemicals and differ in the exposure conditions and effect parameters examined. The aims of the present study were 1) to explore behavioral responses of Daphnia magna exposed to different toxicants, 2) to compare behavioral effect profiles with regard to chemical modes of action, and 3) to determine the sensitivity and response time of behavioral parameters in a new multi-cell exposure system named Multi-DaphTrack compared with currently utilized tests. Twelve compounds covering different modes of toxic action were selected to sample a wide range of potential effect profiles. Acute standard immobilization tests and 48 h of behavioral tracking were performed in the customized Multi-DaphTrack system and a single-cell commercialized biological early warning system. Contrasting behavioral profiles were observed for average speed (i.e., intensity, time of effect onset, effect duration), but no distinct behavioral profiles could be drawn from the chemical mode of action. Most compounds tested in the Multi-DaphTrack system induced an early and significant average speed increase at concentrations near or below the 10% effective concentration (48 h) of the acute immobilization test, demonstrating that the Multi-DaphTrack system is fast and sensitive. To conclude, behavior endpoints could be used as an alternative or complement to the current acute standard test or chemical analysis for the predictive evaluation of ecotoxic effects of effluents or water bodies.
Assuntos
Comportamento Animal/efeitos dos fármacos , Daphnia/efeitos dos fármacos , Poluentes Químicos da Água/toxicidade , Animais , Inibidores da Colinesterase/química , Inibidores da Colinesterase/toxicidade , Daphnia/metabolismo , Agonistas GABAérgicos/química , Agonistas GABAérgicos/toxicidade , Antagonistas GABAérgicos/química , Antagonistas GABAérgicos/toxicidade , Entorpecentes/química , Entorpecentes/toxicidade , Bloqueadores dos Canais de Sódio/química , Bloqueadores dos Canais de Sódio/toxicidade , Testes de Toxicidade Aguda , Poluentes Químicos da Água/químicaRESUMO
Elevating GABA levels in the synaptic cleft by inhibiting its reuptake carrier GAT1 is an established approach for the treatment of CNS disorders like epilepsy. With the increasing availability of crystal structures of transmembrane transporters, structure-based approaches to elucidate the molecular basis of ligand-transporter interaction also become feasible. Experimental data guided docking of derivatives of the GAT1 inhibitor tiagabine into a protein homology model of GAT1 allowed derivation of a common binding mode for this class of inhibitors that is able to account for the distinct structure-activity relationship pattern of the data set. Translating essential binding features into a pharmacophore model followed by in silico screening of the DrugBank identified liothyronine as a drug potentially exerting a similar effect on GAT1. Experimental testing further confirmed the GAT1 inhibiting properties of this thyroid hormone.
Assuntos
Agonistas GABAérgicos/metabolismo , Proteínas da Membrana Plasmática de Transporte de GABA/química , Proteínas da Membrana Plasmática de Transporte de GABA/metabolismo , Simulação de Acoplamento Molecular , Ácidos Nipecóticos/metabolismo , Tri-Iodotironina/farmacologia , Ácido gama-Aminobutírico/metabolismo , Simulação por Computador , Agonistas GABAérgicos/química , Células HEK293 , Ensaios de Triagem em Larga Escala , Humanos , Modelos Moleculares , Estrutura Molecular , Ácidos Nipecóticos/química , Relação Estrutura-Atividade , Tiagabina , Tri-Iodotironina/químicaRESUMO
The role of GABA-A receptors in psychotropic effects of pyrrolo[1,2-a][1,4]diazepine derivatives GMAL-24 and GMAL-27 has been studied on an operant method with liquid reinforcement of drug discrimination in male Wistar rats. It is established that, in substitution tests, GMAL-24 (2, 5, 10 mg/kg) and GMAL-27 (2, 5, 10 mg/kg) do not produce interoceptive effects of phenazepam (1 mg/kg) and fail to inhibit interoceptive effects of corasol (20 mg/kg). The obtained results indicate that pyrrolo[1,2-a][1,4]diazepine derivatives do not exhibit GABA-A receptor-positive modulator properties in vivo.
Assuntos
Azepinas/farmacologia , Benzodiazepinas/farmacologia , Aprendizagem por Discriminação/efeitos dos fármacos , Agonistas GABAérgicos/farmacologia , Psicotrópicos/farmacologia , Receptores de GABA-A/metabolismo , Animais , Azepinas/química , Condicionamento Operante/efeitos dos fármacos , Condicionamento Operante/fisiologia , Aprendizagem por Discriminação/fisiologia , Agonistas GABAérgicos/química , Antagonistas GABAérgicos/farmacologia , Injeções Intraperitoneais , Masculino , Pentilenotetrazol/farmacologia , Psicotrópicos/química , Ratos , Ratos WistarRESUMO
Ionotropic GABA receptors are the targets for several classes of insecticides. One of the most widely-studied insect GABA receptors is RDL (resistance to dieldrin), originally isolated from Drosophila melanogaster. RDL undergoes alternative splicing and RNA editing, which influence the potency of GABA. Most work has focussed on minority isoforms. Here, we report the first characterisation of the predominant native splice variant and RNA edit, combining functional characterisation with molecular modelling of the agonist-binding region. The relative order of agonist potency is GABA> muscimol> TACA> ß-alanine. The I/V edit does not alter the potency of GABA compared to RDLbd. Docking calculations suggest that these agonists bind and activate RDLbdI/V through a similar binding mode. TACA and ß-alanine are predicted to bind with lower affinity than GABA, potentially explaining their lower potency, whereas the lower potency of muscimol and isoguvacine cannot be explained structurally from the docking calculations. The A301S (resistance to dieldrin) mutation reduced the potency of antagonists picrotoxin, fipronil and pyrafluprole but the I/V edit had no measurable effect. Ivermectin suppressed responses to GABA of RDLbdI/V, RDLbd and RDLbdI/VA301S. The dieldrin resistant variant also showed reduced sensitivity to Ivermectin. This study of a highly abundant insect GABA receptor isoform will help the design of new insecticides.
Assuntos
Proteínas de Drosophila/metabolismo , Drosophila/metabolismo , Agonistas GABAérgicos/farmacologia , Ivermectina/farmacologia , Modelos Moleculares , Pirazóis/farmacologia , Receptores de GABA-A/metabolismo , Animais , Primers do DNA/genética , Drosophila/genética , Proteínas de Drosophila/química , Agonistas GABAérgicos/química , Ivermectina/química , Simulação de Acoplamento Molecular , Oócitos/metabolismo , Técnicas de Patch-Clamp , Ligação Proteica , Isoformas de Proteínas/metabolismo , Pirazóis/química , Receptores de GABA-A/química , Xenopus laevisRESUMO
BACKGROUND: R-etomidate possesses unique desirable properties but potently suppresses adrenocortical function. Consequently, efforts are being made to define structure-activity relationships with the goal of designing analogues with reduced adrenocortical toxicity. The authors explored the pharmacological impact of modifying etomidate's chiral center using R-etomidate, S-etomidate, and two achiral etomidate analogues (cyclopropyl etomidate and dihydrogen etomidate). METHODS: The γ-aminobutyric acid type A receptor modulatory potencies of drugs were assessed in oocyte-expressed α1(L264T)ß3γ2L and α1(L264T)ß1γ2L γ-aminobutyric acid type A receptors (for each drug, n = 6 oocytes per subtype). In rats, hypnotic potencies and durations of action were measured using a righting reflex assay (n = 26 to 30 doses per drug), and adrenocortical potencies were quantified by using an adrenocorticotropic hormone stimulation test (n = 20 experiments per drug). RESULTS: All four drugs activated both γ-aminobutyric acid type A receptor subtypes in vitro and produced hypnosis and suppressed adrenocortical function in rats. However, drug potencies in each model ranged by 1 to 2 orders of magnitude. R-etomidate had the highest γ-aminobutyric acid type A receptor modulatory, hypnotic, and adrenocortical inhibitory potencies. Respectively, R-etomidate, S-etomidate, and cyclopropyl etomidate were 27.4-, 18.9-, and 23.5-fold more potent activators of receptors containing ß3 subunits than ß1 subunits; however, dihydrogen etomidate's subunit selectivity was only 2.48-fold and similar to that of propofol (2.08-fold). S-etomidate was 1/23rd as potent an adrenocortical inhibitor as R-etomidate. CONCLUSION: The linkage between the structure of etomidate's chiral center and its pharmacology suggests that altering etomidate's chiral center may be used as part of a strategy to design analogues with more desirable adrenocortical activities and/or subunit selectivities.
Assuntos
Anestésicos Intravenosos/química , Anestésicos Intravenosos/farmacologia , Carbono/química , Etomidato/análogos & derivados , Etomidato/farmacologia , Córtex Suprarrenal/efeitos dos fármacos , Doenças do Córtex Suprarrenal/induzido quimicamente , Doenças do Córtex Suprarrenal/patologia , Anestésicos Intravenosos/toxicidade , Animais , Etomidato/química , Feminino , Agonistas GABAérgicos/síntese química , Agonistas GABAérgicos/química , Agonistas GABAérgicos/farmacologia , Hipnóticos e Sedativos/síntese química , Hipnóticos e Sedativos/química , Hipnóticos e Sedativos/farmacologia , Indicadores e Reagentes , Dose Letal Mediana , Masculino , Conformação Molecular , Ratos , Ratos Sprague-Dawley , Receptores de GABA-A/efeitos dos fármacos , Solubilidade , Estereoisomerismo , Relação Estrutura-Atividade , Xenopus laevisRESUMO
Structures of integral membrane receptors provide valuable models for drug-receptor interactions across many important classes of drug targets and have become much more widely available in recent years. However, it remains to be determined to what extent these images are relevant to human receptors in their biological context and how subtle issues such as subtype selectivity can be informed by them. The high precision structural modifications enabled by unnatural amino acid mutagenesis on mammalian receptors expressed in vertebrate cells allow detailed tests of predictions from structural studies. Using the Cys-loop superfamily of ligand-gated ion channels, we show that functional studies lead to detailed binding models that, at times, are significantly at odds with the structural studies on related invertebrate proteins. Importantly, broad variations in binding interactions are seen for very closely related receptor subtypes and for varying drugs at a given binding site. These studies highlight the essential interplay between structural studies and functional studies that can guide efforts to develop new pharmaceuticals.
Assuntos
Preparações Farmacêuticas/química , Receptores de Superfície Celular/química , Aminoácidos/genética , Animais , Sítios de Ligação , Agonistas GABAérgicos/química , Agonistas GABAérgicos/farmacologia , Humanos , Ativação do Canal Iônico , Ligantes , Mutação , Agonistas Nicotínicos/química , Agonistas Nicotínicos/farmacologia , Preparações Farmacêuticas/metabolismo , Conformação Proteica , Subunidades Proteicas/química , Subunidades Proteicas/genética , Subunidades Proteicas/metabolismo , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismo , Receptores de GABA/química , Receptores de GABA/genética , Receptores de GABA/metabolismo , Receptores de Glicina/agonistas , Receptores de Glicina/química , Receptores de Glicina/genética , Receptores de Glicina/metabolismo , Receptores Nicotínicos/química , Receptores Nicotínicos/genética , Receptores Nicotínicos/metabolismo , Receptores 5-HT3 de Serotonina/química , Receptores 5-HT3 de Serotonina/genética , Receptores 5-HT3 de Serotonina/metabolismo , Agonistas do Receptor 5-HT3 de Serotonina/química , Agonistas do Receptor 5-HT3 de Serotonina/farmacologiaRESUMO
Insomnia is a prominent modern disease that affects an increasing population. Undesirable side effects of commercial drugs highlight the need to develop novel insomnia drugs. Virtual screening of traditional chinese medicine Database@Taiwan (TCM Database@Taiwan) identified 2-O-Caffeoyl tartaric acid (1), 2-O-Feruloyl tartaric acid (2), and Mumefural (3) as potential agonists for both gamma-amino butyric acid (GABA) or benzodiazepine (BZ) binding sites. The TCM candidates exhibited higher affinity than GABA and Zolpidem, a phenomenon that could be attributed to higher quantity of stabilizing H-bonds. Efficacy profiles using support vector machines and pharmacophore contour also suggest drug potential of the TCM candidates. Fragments added to the de novo derivatives 3a, 3b, 3c for GABA binding site, and 1a, 2a, and 3d for BZ binding site contributed to new binding sites and structural stability, further optimizing binding to GABA or BZ binding sites. Increased opening of the ion channel by candidate ligands provide strong support for their potential biological functions. The dual binding properties of the TCM candidates present a unique opportunity to develop twin-targeting drugs with less side effects. Derivative structures can be used as starting points for developing high affinity GABAA receptor agonists with specificity towards GABA binding site and BZ binding site.
Assuntos
Ácidos Cafeicos/química , Ácido Cítrico/análogos & derivados , Ácidos Cumáricos/química , Medicamentos de Ervas Chinesas/química , Furanos/química , Agonistas GABAérgicos/química , Receptores de GABA-A/química , Distúrbios do Início e da Manutenção do Sono/terapia , Tartaratos/química , Sítios de Ligação , Ácido Cítrico/química , Bases de Dados de Compostos Químicos , Humanos , Medicina Tradicional Chinesa , Simulação de Dinâmica Molecular , Ácido gama-Aminobutírico/químicaRESUMO
Designing potent and subtype-selective ligands with therapeutic value requires knowledge about how endogenous ligands interact with their binding site. 4-Amino-3-hydroxybutanoic acid (GABOB) is an endogenous ligand found in the central nervous system in mammals. It is a metabolic product of GABA, the major inhibitory neurotransmitter. Homology modeling of the GABA(C) ρ(1) receptor revealed a potential H-bond interaction between the hydroxyl group of GABOB and threonine 244 (T244) located on loop C of the ligand binding site of the ρ(1) subunit. Using site-directed mutagenesis, we examined the effect of mutating T244 on the efficacy and pharmacology of GABOB and various ligands. It was found that mutating T244 to amino acids that lacked a hydroxyl group in their side chains produced GABA insensitive receptors. Only by mutating ρ(1)T244 to serine (ρ(1)T244S) produced a GABA responsive receptor, albeit 39-fold less sensitive to GABA than ρ(1)wild-type. We also observed changes in the activities of the GABA(C) receptor partial agonists, muscimol and imidazole-4-acetic acid (I4AA). At the concentrations we tested, the partial agonists antagonized GABA-induced currents at ρ(1)T244S mutant receptors (Muscimol: ρ(1)wild-type, EC(50) = 1.4 µM; ρ(1)T244S, IC(50) = 32.8 µM. I4AA: ρ(1)wild-type, EC(50) = 8.6 µM; ρ(1)T244S, IC(50) = 21.4 µM). This indicates that T244 is predominantly involved in channel gating. R-(-)-GABOB and S-(+)-GABOB are full agonists at ρ(1)wild-type receptors. In contrast, R-(-)-GABOB was a weak partial agonist at ρ(1)T244S (1 mM activates 26% of the current produced by GABA EC(50) versus ρ(1)wild-type, EC(50) = 19 µM; I(max) 100%), and S-(+)-GABOB was a competitive antagonist at ρ(1)T244S receptors (ρ(1)wild-type, EC(50) = 45 µM versus ρ(1)T244S, IC(50) = 417.4 µM, K(B) = 204 µM). This highlights that the interaction of GABOB with T244 is enantioselective. In contrast, the potencies of a range of antagonists tested, 3-aminopropyl(methyl)phosphinic acid (3-APMPA), 3-aminopropylphosphonic acid (3-APA), S- and R-(3-amino-2-hydroxypropyl)methylphosphinic acid (S-(-)-CGP44532 and R-(+)-CGP44533), were not altered. This suggests that T244 is not critical for antagonist binding. Receptor gating is dynamic, and this study highlights the role of loop C in agonist-evoked receptor activation, coupling agonist binding to channel gating.